Oppenheimer Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $58

Oppenheimer analyst Steven Lichtman maintains $Tandem Diabetes Care(TNDM.US)$ with a buy rating, and adjusts the target price from $55 to $58.According to TipRanks data, the analyst has a success rate

Futu NewsJun 10 07:31 · Ratings

Express News | Tandem Diabetes Care: Oppenheimer raises target price from $47 to $58.

BreakingsJun 10 07:23

Express News | Tandem Diabetes Care, Inc. : Oppenheimer Raises Target Price to $58 From $47

BreakingsJun 10 07:21

AMD To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Susquehanna

BenzingaJun 10 06:54

Tandem Diabetes Care Is Maintained at Outperform by Oppenheimer

Tandem Diabetes Care Is Maintained at Outperform by Oppenheimer

Dow JonesJun 10 06:32

Oppenheimer Maintains Outperform on Tandem Diabetes Care, Raises Price Target to $58

Oppenheimer analyst Steven Lichtman maintains Tandem Diabetes Care with a Outperform and raises the price target from $47 to $58.

Analyst UpgradesJun 10 06:22